หน้าแรก
ค้นหา
Patient Selection for Upfront Ibrutinib
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
แสดงข้อมูลเพิ่มเติม 1
Patient Selection for Upfront Ibrutinib
Upfront Ibrutinib in CLL
Patient Selection for CLL Treatment
Front-line use of ibrutinib for CLL in a real-world setting
Dr Dorritie on Unanswered Questions Regarding Upfront Treatment Selection in CLL
Upfront Ibrutinib: RESONATE-2 Trial
Dr. Jones on Long-Term Outcomes With Ibrutinib in CLL
Ibrutinib in Younger, but Unfit Patients
Clinical Significance of Upfront Ibrutinib in CLL
Ibrutinib in Older Patients with Newly-Diagnosed CLL
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events
Examining Issues Surrounding Initiation and Discontinuation of Ibrutinib
Dr. Pinilla-Ibarz on Ibrutinib's Efficacy in Treating High-Risk Patients With CLL
Options for Upfront Therapy in MCL
Initiation of Up-front Therapy for CLL
Debate: Best Frontline Regimen for a CLL Patient Aged 60 Who Requires Therapy - Ibrutinib
Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLL
Dr. Kahl Discusses the Potential of Frontline Ibrutinib in MCL
Dr. Kay Discusses the Role of Ibrutinib in CLL
Progression on Frontline Ibrutinib in CLL
